Clinical trials: Otorhinolaryngologic Neoplasms
Schwannoma, Vestibular
CyberKnife Radiotherapy for the Treatment of Schwannomas
Historically, the management of schwannomas has relied primarily on observation, surgery, or conventional radiotherapy techniques.
- Trial name
- Schwannomas (NCT07801560)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hartmann Oncology Radiotherapy Group, France
SBRT
SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
In resectable locally advanced oral cavity cancer and oropharyngeal cancer, SBRT with the total dose of 18 Gy by three fractions will be delivered to the primary tumor and metastatic lymph nodes every other day.
- Trial name
- NCT06219980
- Testing
- SBRT+chemoimmunotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Dysphagia, Non-Small Cell Lung Cancer
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if palifermin will reduce the incidence of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for treatment of unresectable stage III…
- Conditions
- Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT00094861
- Testing
- Palifermin, Radiotherapy, Paclitaxel
- Volunteers
- 100 people
- Sponsor
- Swedish Orphan Biovitrum
Acoustic Neuroma
RGD PET/MRI in Sporadic Vestibular Schwannoma
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E[c(RGDyK)]2 in patients with sporadic Vestibuarl Schwannomas.
- Trial name
- NCT03393689
- Testing
- One injection of 68Ga-NODAGA-E[c(RGDyK)]2
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Head and Neck Cancer
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003182
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hope Cancer Institute, Inc.
Malignant Esophageal Strictures
EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX
This is a prospective, single blinded, randomized study of EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve for the treatment of malignant strictures of the lower esophagus.
- Trial name
- NCT02159898
- Testing
- EndoMAXX Endoluminal Valve Technology (EVT), EndoMAXX
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Merit Medical Systems, Inc.
Nasopharyngeal Carcinoma
Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
The goal of this clinical trial is to compare surgery plus reduced target chemoradiotherapy with surgery plus reduced dose chemoradiotherapy in newly diagnosed operable Nasopharyngeal Carcinoma.The main questions it aims to…
- Trial name
- NCT06529562
- Testing
- Surgery combined with Target-reduction intensity-modulated radiotherapy, Surgery combined with Dose-reduction intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Ming-Yuan Chen
Oropharyngeal Squamous Cell Cancer
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
Investigators will determine whether a treatment paradigm of up-front neck dissection, to more accurately pathologically stage patients, minimizing the number of treatment modalities in patients with low risk oropharyngeal…
- Trial name
- NCT02784288
- Testing
- Neck Dissection, Standard-of-Care (SOC) Transoral Surgery of Primary Site, SOC Radiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancers, Head and Neck Cancers - Nasopharyngeal
Predictive Tools in Head and Neck Cancer Patients Undergoing Radiotherapy
The ITHACA study aims to improve the treatment of head and neck cancer by developing a predictive tool that helps doctors personalize care for each patient.
- Conditions
- Head and Neck Cancers, Head and Neck Cancers - Nasopharyngeal, Oral Cavity Cancer, Oropharyngeal Cancers
- Trial name
- ITHACA (NCT06806683)
- Testing
- intensity modulated radiotherapy
- Where
- Italy
- Volunteers
- 915 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nasopharyngeal Carcinoma
To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer
Nasopharyngeal carcinoma (NPC) is endemic in our region and is the 9th most common cancer in Hong Kong. Traditionally diagnosis has been through a nasoendoscopic examination of the nasopharynx with white light followed by a…
- Trial name
- NCT04419324
- Testing
- transoral flexible endoscope with magnifying narrow band imaging
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Head and Neck Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00675233
- Testing
- HPPH, laser therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Roswell Park Cancer Institute
Oropharynx Cancer, HPV-Related Carcinoma
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3.
- Trial name
- ARTHOUSE (NCT06234748)
- Testing
- Radiation, Platinum based chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acoustic Neuroma, Labyrinthitis Ossificans
Maintaining Cochlear Patency After VIIIth Nerve Surgery
Tumors arising from the VIIIth Nerve (vestibulo-cochlear nerve) typically present with progressive unilateral hearing loss and tinnitus.
- Conditions
- Acoustic Neuroma, Labyrinthitis Ossificans, Profound Hearing Impairment
- Trial name
- NCT03261726
- Testing
- MedEl Test Electrode Placer
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Recurrent Nasopharyngeal Carcinoma
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
The purpose of this study is to evaluate the efficacy and safety of chemotherapy with Lobaplatin and 5-FU, in Recurrent Local or Distant Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03210389
- Testing
- Lobaplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk…
- Trial name
- NCT07540390
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms, Laryngeal Disease
AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study
An artificial intelligence-assisted system is trained and validated by collecting nasopharyngolaryngoscopy images from patients.
- Trial name
- NCT07326358
- Testing
- Diagnostic
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Laryngeal Cancer, Hypopharynx Cancer
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable laryngeal/hypopharyngeal carcinoma.
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- INSIGHT (NCT04995120)
- Testing
- chemotherapy TP regimen combined with Toripalimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.
- Trial name
- NCT03558191
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Recurrent Pharyngeal Cancer
Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent pharyngeal cancer.
- Trial name
- NCT02849327
- Testing
- Cryosurgery, NK immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.